Analyst Scoreboard: 4 Ratings For Akoya Biosciences
Ratings for Akoya Biosciences (NASDAQ:AKYA) were provided by 4 analysts in the past three months, showcasing a mix…
Why Alibaba Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session
Shares of Alibaba Group Holding Limited (NYSE:BABA) fell sharply during Tuesday’s session following mixed first-quarter financial results. The…
12 Health Care Stocks Moving In Tuesday’s Intraday Session
Gainers Delcath Systems (NASDAQ:DCTH) stock rose 33.2% to $7.19 during Tuesday’s regular session. The company’s market cap stands…
Why Alcon Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
Shares of Alcon Inc. (NYSE:ALC) rose sharply in today’s pre-market trading following better-than-expected first-quarter earnings. Alcon posted adjusted…
12 Health Care Stocks Moving In Tuesday’s Pre-Market Session
Gainers CareCloud (NASDAQ:CCLDO) stock moved upwards by 46.1% to $15.5 during Tuesday’s pre-market session. Syra Health (NASDAQ:SYRA) shares…
12 Health Care Stocks Moving In Monday’s After-Market Session
Gainers Aesthetic Medical Intl (NASDAQ:AIH) shares moved upwards by 23.3% to $0.57 during Monday’s after-market session. The market…
Akoya Biosciences And NeraCare Enter Exclusive Agreement To Enable Personalized Therapy Selection For Early-Stage Melanoma Patients
Akoya Biosciences, Inc. (NASDAQ:AKYA), The Spatial Biology Company®, and NeraCare, a leading developer of laboratory tests for the prognosis of melanoma patients, announced an exclusive agreement today under which
Akoya Biosciences And Shanghai KR Pharmtech Announce Chinese Regulatory Agency Premarket Approval For KR-HT5 In China To Support Next Generation Pathology Clinical Workflows
Akoya Biosciences, Inc. (NASDAQ:AKYA), The Spatial Biology Company®, and Shanghai KR Pharmtech, a leading company providing molecular diagnostic solutions in China, have jointly announced that KR-HT5, which Akoya
Akoya Biosciences Announces Preliminary Financial Results For Q4 And FY23 And Provides 2024 Outlook; Sees Q4 Revenue $25.5M-$26.5M Vs $26.28M Est.; FY23 Revenue $95.6M-$96.6M Vs $96.6M Est.; Expects FY24 Revenue To Grow 20%+
Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2023, and projected year end 2023
Akoya Biosciences And Thermo Fisher Scientific Announced Earlier Sunday, A License And Distribution Agreement To Deliver Spatial Multiomics Workflow
Akoya Biosciences, Inc., (NASDAQ:AKYA), The Spatial Biology Company®, today announced that it has entered into a license and distribution agreement with Thermo Fisher Scientific, Inc. The agreement enables Akoya to